www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

NLG919 (RG6078)

产品编号: D50917

CAS: 1402836-58-1

分子式: C18H22N2O

纯度: ≥98%

InChi: InChI=1S/C18H22N2O/c21-18(13-6-2-1-3-7-13)10-16-14-8-4-5-9-15(14)17-11-19-12-20(16)17/h4-5,8-9,11-13,16,18,21H,1-3,6-7,10H2

InChi Key: YTRRAUACYORZLX-UHFFFAOYSA-N

Smiles: OC(CC1C2=CC=CC=C2C2=CN=CN21)C1CCCCC1

外观: 固体粉末

作用通路: Indoleamine 2, 3-Dioxygenase (IDO)

溶解性: DMSO up to 50 mM

保存条件: Store in dry, dark place for one year.

产品介绍: NLG919 is a potent, selective and orally bioavailable IDO (indoleamine-(2, 3)-dioxygenase) pathway inhibitor with Ki ~7 nM (EC50 ~75 nM) in vitro and in cell based assays. Oral administration of NLG919 reduces the [Kyn] in plasma and tissue by ~ 50%. Using human IDO+ pDCs in allogeneic MLR reactions, NLG919 potently blocked IDO- induced T cell suppression and restored robust T cell responses with an EC50 ~90 nM. NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I or pmel- 1) in vitro, (ED50 ~130 nM) using mouse IDO+ pDCs from tumor-draining lymph nodes. In mice bearing large established B16F10 tumors, administration of NLG919 markedly enhanced the antitumor responses of naive, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. Currently NLG919 is in phase I trial for the treatment of immunosuppression associated with cancer.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.